Sol-Gel Technologies Ltd. (SLGL) is a Healthcare stock trading at $72.94 (as of 2026-06-18), with a market capitalization of $205.76M and a trailing P/E of -33.7. Figures are sourced from first-party U.S. SEC EDGAR filings and market data.
Sol-Gel Technologies is a clinical-stage pharmaceutical company developing topical dermatology products that use its microencapsulation-based drug delivery platform. Its pipeline includes late-stage candidates for acne vulgaris and papulopustular rosacea, earlier-stage programs, and also development of generic topical dermatology products, with collaboration involvement from Perrigo.